Business Context and Reporting Period
Company: Leap Therapeutics, Inc. (Note: Input metadata referenced "Cypherpunk Technologies Inc.", but the filing text identifies the registrant as Leap Therapeutics, Inc.)
Filing Type: Form 8-K (Current Report)
Report Date: October 6, 2025
Event: Entry into a Material Definitive Agreement for a private placement of securities and a strategic pivot to a digital asset treasury strategy.
Key Financial Metrics and Transaction Details
Transaction Overview: Private placement closed on October 8, 2025.
Gross Proceeds: Approximately $58.88 million USD (before fees and expenses).
Securities Issued:
- Common Stock: 15,212,311 shares at $0.52064 per share.
- Pre-Funded Warrants: 80,768,504 warrants at $0.51964 per warrant (exercise price $0.001).
- Common Warrants: 71,985,605 warrants (exercise price $0.5335, 10-year term).
Placement Agent Fees: $1.5 million total ($1.0 million cash; $0.5 million in warrants for 4,000,000 shares).
Use of Proceeds: Primary allocation to a digital asset treasury strategy (investment in tokens); secondary allocation to therapeutic programs (FL-501 and sirexatamab), transaction costs, and working capital.
Material Changes and Governance
Strategic Pivot: The company is shifting focus to include a digital asset treasury strategy, a significant change from its traditional biopharmaceutical operations.
Board Composition: The Board of Directors was expanded to 12 members.
Lead Investor Rights: Winklevoss Treasury Investments, LLC (Lead Investor) secured the right to nominate two directors, one of whom will serve as Chair of the Board, contingent on maintaining specific ownership thresholds (16.7% for two seats; 8.33% for one seat).
Outlook, Risks, and Contingencies
Outlook: Management anticipates value creation through the digital asset treasury strategy and continued development of therapeutic programs.
Key Risks:
- High volatility of cryptocurrency prices and correlation with the company's stock price.
- Regulatory uncertainty regarding digital assets and tax treatment.
- Failure to realize anticipated benefits of the treasury strategy.
- Dilution of existing shareholders due to the issuance of significant warrant coverage.
Restrictions: The company is restricted from issuing or selling securities for 30 days following the closing date, subject to exceptions. Placement Agent Warrants are subject to a 6-month lock-up period.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the $1.5 million placement fee and other transaction expenses.
- Confirm the specific digital assets intended for purchase and the custody arrangements for these assets.
- Review the full text of the Lead Investor Agreement (Exhibit 10.3) to understand the extent of Winklevoss Treasury Investments' control over board decisions.
- Assess the dilution impact of the 152+ million shares underlying the Pre-Funded and Common Warrants.
- Monitor the filing of the Resale Registration Statement, which must be filed within 30 days of a purchaser's demand.